SCHEMBL3562032

SCHEMBL3562032

CCCCOc1ccc(S(=O)(=O)Nc2ccc(OCCOc3ccc(C(=O)O)cc3)cc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.71
LMNA P02545 1/20 0.71
WDR5 P61964 1/20 0.69
GFER P55789 1/20 0.63
TDP1 Q9NUW8 1/20 0.62
FABP4 P15090 1/20 0.60
TP53 P04637 2/20 0.59
TSHR P16473 2/20 0.59
MAPT P10636 2/20 0.59
PLA2G4B P0C869 2/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
CA12 O43570 1/20 0.57
CA1 P00915 1/20 0.57
CA2 P00918 1/20 0.57
CA9 Q16790 1/20 0.57
RARB P10826 4/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3551452 0.93 SMN1; SMN2 (0.63) SMN1; SMN2LMNAWDR5GFERTDP1
SCHEMBL3554413 0.93 SMN1; SMN2 (0.65) SMN1; SMN2LMNAWDR5GFERTDP1
SCHEMBL3554081 0.90 LMNA (0.59) SMN1; SMN2LMNAWDR5GFERTDP1
SCHEMBL3564489 0.90 GFER (0.60) SMN1; SMN2LMNAWDR5GFERTDP1
SCHEMBL3559760 0.90 HDAC1 (0.64) SMN1; SMN2LMNAWDR5GFERTDP1
SCHEMBL3555882 0.90 GFER (0.79) SMN1; SMN2LMNAWDR5GFERTDP1
SCHEMBL5322258 0.88 LMNA (0.77) SMN1; SMN2LMNAWDR5TP53TSHR
SCHEMBL3563809 0.88 MEN1 (0.62) SMN1; SMN2LMNAWDR5GFERTDP1
SCHEMBL3553373 0.87 AR (0.62) SMN1; SMN2LMNAWDR5GFERTDP1
SCHEMBL25214605 0.87 ABCG2 (0.60) SMN1; SMN2LMNAWDR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US claimed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US claimed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 SMN1; SMN2 4522/4885LMNA 2120/4885WDR5 1795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.